Picture of RegenETP, logo

RGTPQ — RegenETP, News Story

0.000.00%
us flag iconLast trade - 00:00
FinancialsHighly SpeculativeMicro Cap

PolarityTE Inc expected to post a loss of 10 cents a share - Earnings Preview

* PolarityTE Inc  PTE.OQ   PTE.O  is expected to show a rise in
quarterly revenue when it reports results on August 12. 
* The Salt Lake City, Utah-based company is expected to report 
 a 41.0% increase in revenue to $3.195 million from $2.27
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for PolarityTE Inc is for a
loss of 10 cents per share. For the same quarter last year, the
company reported a loss of 33 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for PolarityTE Inc
is $2.75​, about 69.2% above​ its last closing price
of $0.85. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.13       -0.12      -0.16     Missed  -37.1
 Dec. 31 2020  -0.23       -0.16      -0.26     Missed  -57.6
 Sep. 30 2020  -0.20       -0.21      -0.18     Beat    12.6​
 Jun. 30 2020  -0.35       -0.38      -0.33     Beat    12.4
 Mar.          -0.49​      -0.52      -0.53     Missed  -2.5​
 31​ 2020​                                              
 Dec. 31 2019  -0.83       -0.90      -0.76     Beat    15.3​
 Sep. 30 2019  -0.96       -1.00      -0.87     Beat    12.8
 Jun. 30 2019  -1.04       -1.05      -0.92     Beat    12.4
 This summary was machine generated August 10 at 23:43 GMT.  All
figures in US dollars unless otherwise stated

Recent news on RegenETP,

See all news